Department of Urology, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Braz J Med Biol Res. 2009 Oct;42(10):963-7. doi: 10.1590/s0100-879x2009005000021. Epub 2009 Sep 4.
We investigated the effectiveness of celecoxib in reducing symptoms in patients with difficult chronic pelvic pain syndrome (CPPS), NIH category IIIA. Sixty-four patients with category IIIA CPPS were randomized into two groups of 32 subjects each. One group was treated with celecoxib (200 mg daily) and the other with placebo. All patients underwent treatment for 6 weeks and were evaluated clinically before (baseline) and after 1, 2, 4, 6, and 8 weeks of treatment. The evaluation included the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and a subjective global assessment (SGA). Repeated measures analysis of variance was used to evaluate treatment and time effects and their interaction. A decrease (means +/- SD) in total NIH-CPSI score from 23.91 +/- 5.27 to 15.88 +/- 2.51 in the celecoxib group and from 24.25 +/- 5.09 to 19.50 +/- 2.50 in the placebo group was observed during treatment (0 to 6 weeks). A statistically significant decrease was observed in pain subscore (P < 0.006), quality of life subscore (P < 0.032) and total NIH-CPSI score (P < 0.015) after 2, 4 and 6 weeks, but not in urinary subscore. In addition, 38% of the celecoxib and 13% of the placebo subjects had at least a moderate improvement in SGA. The trend was similar for the NIH-CPSI scores. However, the response to treatment in terms of total NIH-CPSI score or subscore was not significantly different from placebo after interruption of treatment for 2 weeks. Our results show that celecoxib provides significant symptomatic improvement limited to the duration of the therapy in patients with difficult category IIIA CPPS compared to placebo.
我们研究了塞来昔布治疗困难型慢性骨盆疼痛综合征（CPPS）NIH IIIA 类患者症状的疗效。64 例 IIIA 类 CPPS 患者随机分为两组，每组 32 例。一组用塞来昔布（200mg/d）治疗，另一组用安慰剂治疗。所有患者均接受 6 周治疗，并在治疗前（基线）及治疗后 1、2、4、6、8 周进行临床评估。评估包括 NIH 慢性前列腺炎症状指数（NIH-CPSI）和主观整体评估（SGA）。采用重复测量方差分析评估治疗和时间的效果及其相互作用。塞来昔布组 NIH-CPSI 总分从 23.91±5.27 降至 15.88±2.51，安慰剂组从 24.25±5.09 降至 19.50±2.50（0 至 6 周）。治疗后第 2、4、6 周时疼痛亚评分（P<0.006）、生活质量亚评分（P<0.032）和 NIH-CPSI 总分（P<0.015）显著下降，但尿亚评分无显著下降。此外，塞来昔布组 38%和安慰剂组 13%的患者 SGA 至少有中度改善。NIH-CPSI 评分也有类似趋势。然而，停药 2 周后，塞来昔布组在 NIH-CPSI 总分或亚评分的治疗反应与安慰剂相比无显著差异。我们的结果表明，与安慰剂相比，塞来昔布可显著改善困难型 IIIA 类 CPPS 患者的症状，且疗效局限于治疗期间。
